Radiopharm Theranostics (Radiopharm Theranostics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Radiopharm Theranostics's Free Cash Flow for the six months ended in Dec. 2023 was $-7.88 Mil. Radiopharm Theranostics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Radiopharm Theranostics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Radiopharm Theranostics's current FCF Yield % is -147.20%.

The historical rank and industry rank for Radiopharm Theranostics's FCF Margin % or its related term are showing as below:

RDPTF' s FCF Margin % Range Over the Past 10 Years
Min: -425055.56 Med: -216762.89 Max: -8342.35
Current: -8342.35

During the past 2 years, the highest FCF Margin % of Radiopharm Theranostics was -8342.35%. The lowest was -425055.56%. And the median was -216762.89%.

RDPTF's FCF Margin % is ranked worse than
91% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs RDPTF: -8342.35

Radiopharm Theranostics FCF Margin % Historical Data

The historical data trend for Radiopharm Theranostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics FCF Margin % Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

FCF Margin %

-448,050.00

-8,469.39

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	-	-	-4,147.72	-	-

Competitive Comparison of Radiopharm Theranostics's FCF Margin %

For the Biotechnology subindustry, Radiopharm Theranostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's FCF Margin % falls into.

Radiopharm Theranostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Radiopharm Theranostics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-16.6	/	0.196
	=	-8,469.39 %

Radiopharm Theranostics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.88	/	0
	=	%

Radiopharm Theranostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022